

On February 27, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Karen Karlin

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Yasumichi Hitoshi et al.

Application No.: 10/026,021

Filed: December 21, 2001

For: SAK: MODULATION OF  
CELLULAR PROLIFERATION FOR  
TREATMENT OF CANCER

Confirmation No.: 6123

Examiner: Misook Yu

Art Unit: 1642

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

Also enclosed is a copy of the Search report corresponding to the European application (EP Application No. 02750377.0).


It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination. A Notice of Allowance was mailed on November 30, 2006. This Information Disclosure Statement and the Request for Continued Examination are being filed on or before the due date of the Issue Fee, which is February 28, 2007.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
ASP:kkk

60950025 v1

Substitute for form 1449A&B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/026,021
<i>(Use as many sheets as necessary)</i>				Filing Date	December 21, 2001
				First Named Inventor	Hitoshi, Yasumichi
				Art Unit	1642
				Examiner Name	Misook Yu
Sheet	1	of	1	Attorney Docket Number	021044-001210US

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T <sup>6</sup>

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	1	FODE, Carol, et al., "Constitutive Expression of Murine Sak-a Suppresses Cell Growth and Induces Multinucleation," Molecular and Cellular Biology, 1996, Vol. 16, No. 9, pp 4665-4672.			
	2	HIRAO, Atsushi, et al. "DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2," Science, 2000, Vol. 287, pp 1824-1827.			
	3	KARN, Thomas, et al., "Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis," Oncology Reports, 1997, Vol. 4, pp 505-510.			
	4	LUKAS, Claudia, et al., "DNA Damage-activated Kinase Chk2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology," Cancer Research, 2001, Vol. 61, pp 4990-4993.			
	5	MACMILLAN, Jennifer C., et al., "Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer," Annals of Surgical Oncology, Vol. 8, No. 9, pp 729-740.			

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.